证券代码：000950 证券简称：重药控股 公告编号：2025-070 本公司及董事会全体成员保证公告内容真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 重药控股股份有限公司（以下简称"公司"）第九届董事会第十八次会议决 定召开公司 2025 年第四次临时股东会，现将会议有关事项公告如下： 一、召开会议的基本情况 1.股东会届次：2025 年第四次临时股东会 2.股东会召集人：重药控股股份有限公司董事会 3.会议召开的合法性和合规性：公司第九届董事会第十八次会议审议通过了 《关于召开 2025 年第四次临时股东会的议案》，本次股东会会议召开符合有关 法律、行政法规、部门规章、规范性文件和公司章程的有关规定。 4.会议召开的日期和时间： 重药控股股份有限公司 关于召开 2025 年第四次临时股东会的通知 （1）现场会议召开时间：2025 年 10 月 22 日（星期三）14:30 （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 10 月 22 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间 ...

重药控股股份有限公司 第九届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 证券代码：000950 证券简称：重药控股 公告编号：2025-069 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 重药控股股份有限公司（以下简称"公司"）第九届董事会第十八次会议于 2025年9月29日以通讯表决形式召开，会议通知于2025年9月23日以电子邮件方式 发出。会议应出席董事11人，实际出席会议的董事11人。会议由公司董事长袁泉 主持。本次会议的召开符合《公司法》《公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于增加2025年日常关联交易额度的议案》 具体内容详见同日披露的《关于增加2025年日常关联交易额度的公告》。 表决结果：同意9票，回避2票，反对0票，弃权0票。 关联董事袁泉、魏云回避表决。 本议案经独立董事专门会议审议通过。 （二）审议通过《关于下属子公司调整担保额度的议案》 具体内容详见同日披露的《关于下属子公司调整担保额度的公告》。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 三、备查文件 本议案尚需提交股东会审议。 ...

Core Insights - The Chengdu-Chongqing economic circle has seen its GDP grow from less than 6.3 trillion yuan in 2019 to 8.7 trillion yuan in 2024, marking an increase in its share of the national economy from 6.3% to 6.5% [1] - The brand value of listed companies in the Chengdu-Chongqing region has significantly increased, with Wuliangye and Luzhou Laojiao leading the rankings [2][3] Company Insights - Wuliangye (000858.SZ) ranks first with a brand value of 305.96 billion yuan, followed by Luzhou Laojiao (000568.SZ) at 107.67 billion yuan, and Changan Automobile (000625.SZ) at 84.56 billion yuan [2][3] - The beverage industry in the Chengdu-Chongqing region has seen a brand value increase of 117.02 billion yuan over the past four years, making it the highest among all industries [6][8] Industry Insights - The automotive industry in the region has surpassed a brand value of 100 billion yuan, reaching 123.15 billion yuan in 2025 [6][8] - The equipment industry has doubled the number of listed companies over the past four years, indicating a significant growth in this sector [8][10] - The agricultural sector has experienced a decline in brand value, primarily due to the shift of Tongwei Co., Ltd. (600438.SH) from agriculture to the equipment sector [6][8] Regional Insights - Chengdu has the highest increase in both the total brand value of listed companies and the number of companies listed over the past four years [4][5] - The Chengdu-Chongqing region serves as a strategic support for the Yangtze River Economic Belt and is a key demonstration area for the country's new urbanization efforts [2]

Core Viewpoint - The company aims to enhance its profitability by optimizing its industrial layout, exploring niche markets, and actively seeking new business growth points while consolidating its existing main business [1] Group 1 - The company is focused on strengthening its existing main business [1] - The company plans to optimize its industrial layout [1] - The company intends to explore niche markets [1] Group 2 - The company is actively seeking new business growth points [1]

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

Group 1 - The core point of the article is that Chongqing Pharmaceutical Holdings (000950) clarified its relationship with Hangzhou Xinhang Zhichuang Technology Co., stating that there is no equity relationship between the two companies, but they do have a product purchase and sales cooperation relationship [1]

Group 1 - The core point of the article is the completion of the equity structure change of Chongqing Yijian, the controlling shareholder of Chongqing Pharmaceutical Holdings, which is expected to stabilize the company's strategic direction and business expansion [1][2] - After the equity change, the new ownership structure of Chongqing Yijian is as follows: General Technology Group holds 48%, China Pharmaceutical Health Industry Co., Ltd. holds 27%, and Chongqing Yufu holds 25% [1] - Despite the changes in equity proportions, Chongqing Pharmaceutical Holdings remains under the control of Chongqing Yijian, with the actual controller still being the State-owned Assets Supervision and Administration Commission of the State Council [1] Group 2 - The stable equity structure is expected to help Chongqing Pharmaceutical Holdings maintain continuity in operational decision-making and enhance resource integration among shareholders [2] - This stability is seen as beneficial for consolidating the company's competitive position in the pharmaceutical distribution market [2] - The company has established a comprehensive national pharmaceutical supply chain service network, with over 230 subsidiaries and significant market influence in various provinces [1]

Core Points - The "China Top 500 Enterprises" list for 2024 was released by the China Enterprise Confederation and the China Enterprise Association, ranking companies based on their operating revenue [1] - Ten companies from Chongqing made the list, maintaining the same number as last year [1] Group 1: Chongqing Companies - The ten Chongqing companies listed are: - Seres Group Co., Ltd. (Ranked 190) - Longfor Group Holdings Limited (Ranked 212) - Chongqing Chemical Industry Holding (Group) Co., Ltd. (Ranked 273) - Chongqing Pharmaceutical Holdings Co., Ltd. (Ranked 306) - Jinlong Precision Copper Tube Group Co., Ltd. (Ranked 391) - Chongqing Bosai Mining (Group) Co., Ltd. (Ranked 407) - Chongqing New Oupeng Enterprise (Group) Co., Ltd. (Ranked 446) - Chongqing Rural Commercial Bank Co., Ltd. (Ranked 462) - Chongqing Mechanical and Electrical Holdings (Group) Co., Ltd. (Ranked 463) - Zongshen Industrial Group Co., Ltd. (Ranked 466) [1] Group 2: Top 10 Companies in China - The top 10 companies in the "China Top 500 Enterprises" list based on operating revenue are: 1. State Grid Corporation of China: 394,592,833 million yuan 2. China National Petroleum Corporation: 296,904,813 million yuan 3. China Petroleum and Chemical Corporation: 293,195,627 million yuan 4. China State Construction Engineering Corporation: 218,714,784 million yuan 5. Industrial and Commercial Bank of China: 162,912,600 million yuan 6. Agricultural Bank of China: 141,994,100 million yuan 7. China Construction Bank: 141,483,800 million yuan 8. Bank of China: 126,469,200 million yuan 9. China Railway Engineering Corporation: 116,084,838 million yuan 10. JD.com, Inc.: 115,881,900 million yuan [1][2]

证券代码：000950 证券简称：重药控股 公告编号：2025-068 为进一步做好投资者关系管理工作，增强与广大投资者的互动交流，重药控 股股份有限公司（以下简称"公司"）将参加在重庆证监局指导下，由重庆上市公 司协会联合深圳市全景网络有限公司举办的"重庆辖区上市公司 2025 年投资者 网上集体接待日活动"（以下简称"本次活动"），现将有关事项公告如下： 1.本次活动的时间：2025 年 9 月 25 日（星期四）15:00-17:00。 重药控股股份有限公司 关于参加重庆辖区上市公司 2025 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 2.本次活动的交流网址：本次活动将通过深圳市全景网络有限公司提供的网 上平台，采取网络远程的方式进行，投资者可以登录网址：http://ir.p5w.net 进入 专区页面参与交流。 3.届时公司相关高管人员将通过网络在线交流形式，就投资者所关心的问题， 与投资者进行"一对多"形式的互动交流。欢迎广大投资者积极参与本次活动。 特此公告 重药控股股份有限公司董事会 2025 年 9 月 ...

证券代码：000950 证券简称：重药控股 公告编号：2025-067 重药控股股份有限公司 关于控股股东股权结构拟发生变更的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 2025 年 6 月 19 日，重药控股股份有限公司（以下简称"公司"）披露了《关 于控股股东股权结构拟发生变更的提示性公告》（公告编号：2025-039），公司 控股股东重药医药健康产业有限公司（以下简称"重庆医健"）的股东重庆渝富控 股集团有限公司（以下简称"重庆渝富"）在重庆联合产权交易所集团股份有限公 司（以下简称"重庆联交所"）公开挂牌转让重庆医健 24%股权（以下简称"本次 交易"）。 2025 年 8 月 22 日，公司披露了《关于控股股东股权结构拟发生变更的进展 公告》（公告编号：2025-063），重庆联交所确定本次交易的最终受让方为中国 通用技术（集团）控股有限责任公司（以下简称"通用技术集团"）。交易双方 经协商将按照重庆联交所的相关流程以交易底价 22.06 亿元签订产权交易合同。 2025 年 8 月 27 日，公司披露了《关于控股股东股权结构拟发生变更 ...